ABRA BOUND Paclitaxel 100mg Injection

Product Description

ABRA BOUND Paclitaxel 100mg Injection is a chemotherapy medication used in the treatment of various types of cancer. Paclitaxel, the active ingredient, is a taxane class drug that works by interfering with the ability of cancer cells to divide and grow. It is often used in combination with other cancer treatments.

Key Details about ABRA BOUND Paclitaxel 100mg Injection:

Active Ingredient:

• Paclitaxel (100 mg per vial) is the active ingredient in ABRA BOUND injection. Paclitaxel is a microtubule stabilizer that prevents cancer cells from dividing, thereby inhibiting their growth and causing cell death.

Mechanism of Action:

Paclitaxel works by stabilizing microtubules, which are part of the cell's structure responsible for cell division. By stabilizing these microtubules, Paclitaxel disrupts the normal process of cell division (mitosis), ultimately leading to cell death. This is particularly effective in rapidly dividing cancer cells, which rely on this process for growth and spread.

Indications (Uses):

ABRA BOUND Paclitaxel 100mg Injection is used to treat various cancers, including:

1. Breast Cancer: It can be used in both early-stage and metastatic breast cancer, often in combination with other chemotherapeutic agents.
2. Ovarian Cancer: It is effective for both early-stage and advanced ovarian cancer, typically as part of combination chemotherapy regimens.
3. Non-Small Cell Lung Cancer (NSCLC): Used in combination with other chemotherapy drugs to treat NSCLC.
4. Kaposi's Sarcoma: Paclitaxel is also used in the treatment of Kaposi's sarcoma in patients with AIDS.
5. Head and Neck Cancer: It may be used for advanced head and neck cancers as part of a combination regimen.

Dosage:

• Paclitaxel is typically administered as an intravenous (IV) infusion.
• Common Dosage: The usual dose for adults can vary depending on the type of cancer being treated, the combination regimen, and individual patient factors. For breast cancer, it is often 175 mg/m² IV over 3 hours every 3 weeks.
• Combination Therapy: Paclitaxel is often used with other chemotherapy agents like carboplatin or cyclophosphamide, and the exact dosage regimen will depend on the specific cancer being treated.

The doctor will determine the appropriate dosage based on the patient's medical condition, cancer type, and response to treatment.

Administration:

• Paclitaxel is administered intravenously (IV) by a healthcare provider, typically over a period of 3 hours, although shorter infusion times (e.g., 1 hour) may be used in some cases.
• The solution is usually prepared by a healthcare professional before administration. It is essential to follow the correct infusion protocol to avoid complications.
• Pre-medication: To reduce side effects such as hypersensitivity reactions, patients may be given premedications such as steroids (e.g., dexamethasone), antihistamines, and H2 blockers.

Side Effects:

Common side effects of ABRA BOUND Paclitaxel 100mg Injection include:

• Nausea and vomiting,
• Hair loss (alopecia),
• Fatigue,
• Diarrhea or constipation,
• Mouth sores or stomatitis,
• Low blood counts (e.g., neutropenia or anemia), increasing the risk of infections, bleeding, or fatigue.

Serious side effects may include:

• Hypersensitivity reactions: These can range from mild symptoms like rash or fever to more severe reactions such as difficulty breathing, chest pain, and swelling. These reactions are more likely to occur with the first infusion.
• Bone marrow suppression: Paclitaxel can cause a significant decrease in white blood cells, red blood cells, and platelets, leading to a higher risk of infection, anemia, and bleeding.
• Liver toxicity: It can affect liver function, leading to elevated liver enzymes.
• Peripheral neuropathy: Numbness, tingling, or pain in the hands and feet can occur, particularly with prolonged use of paclitaxel.
• Cardiac issues: In rare cases, paclitaxel may cause heart problems, such as arrhythmias or heart failure.

Precautions:

• Allergic reactions: Paclitaxel may cause hypersensitivity reactions. Patients should be monitored closely during the first infusion, as the risk is higher during this time.
• Bone marrow suppression: Patients may experience a drop in blood cell counts, which can increase the risk of infection or bleeding. Regular blood tests will be required.
• Liver function: Paclitaxel may cause liver toxicity, so liver enzymes should be monitored during treatment.
• Peripheral neuropathy: Patients with a history of nerve problems should be monitored for symptoms like tingling, numbness, or pain in the hands or feet.
• Pregnancy and breastfeeding: Paclitaxel is classified as Category D for pregnancy, meaning it may cause harm to a fetus. It should not be used during pregnancy or while breastfeeding.

Drug Interactions:

Paclitaxel may interact with certain medications, including:

• CYP450 enzyme inhibitors: These drugs can interfere with paclitaxel metabolism, leading to higher levels of paclitaxel in the bloodstream.
• CYP450 enzyme inducers: These drugs can decrease paclitaxel levels, reducing its effectiveness.
• Other chemotherapy drugs: Combination with other chemotherapy agents may increase the risk of side effects like bone marrow suppression or liver toxicity.

Storage:

• Room Temperature: Store the vials of ABRA BOUND Paclitaxel at room temperature (between 20C to 25C or 68F to 77F).
• Avoid freezing or excessive heat, and protect from light.
• Keep out of reach of children.

Conclusion:

ABRA BOUND Paclitaxel 100mg Injection is a chemotherapy medication used in the treatment of several cancers, including breast cancer, ovarian cancer, non-small cell lung cancer, and Kaposi's sarcoma. It works by inhibiting cell division in cancer cells, thereby slowing down their growth and spread. Like many chemotherapy drugs, it can cause side effects such as nausea, hair loss, and bone marrow suppression. Regular monitoring and management of side effects are crucial during treatment.